NAPSRx News: FDA approves Unituxin to treat Pediatric High-Risk Neuroblastoma

By:
 
WASHINGTON - March 10, 2015 - PRLog -- The U.S. Food and Drug Administration (FDA) has approved Unituxin (dinutuximab) from the United Therapeutics Corporation as a part of first-line therapy for pediatric patients with high-risk neuroblastoma. Neuroblastoma typically occurs in children younger than age five and forms from immature nerve cells which usually begins in the adrenal glands and may eventually develop in the abdomen, chest or in nerve tissue or spine.  The National Cancer Institute estimates 100,000 children suffer from neuroblastoma and the occurrence is more common in boys. An estimated 650 new cases of neuroblastoma are diagnosed in the United States each year and patients affected usually have a 40 to 50 percent chance of long term survival regardless of aggressive therapy.

Approval of Unituxin™ was based on improved event-free survival (EFS) and overall survival (OS) in a multicenter, open-label, randomized trial (ANBL0032) conducted by the Children's Oncology Group (COG). "This approval has been a collaborative effort between the National Cancer Institute (NCI), the Children's Oncology Group and United Therapeutics for the first approved therapy for pediatric high-risk neuroblastoma," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer.  "We are grateful for the FDA's thorough review and collaboration on this program, and we look forward to expanding our research efforts in the area of pediatric oncology."

"The FDA approval of dinutuximab represents the culmination of a remarkably productive collaboration between researchers of the NCI-supported Children's Oncology Group, the manufacturing and clinical research groups of NCI, and the oncology team at United Therapeutics," said Malcolm Smith, MD, Ph.D., Associate Branch Chief, Pediatrics in the Cancer Therapy Evaluation Program at NCI.  Children with neuroblastoma will benefit from this collaboration, and the drug development pathway blazed by dinutuximab will likely be followed in the future to develop other novel agents directed against pediatric cancer therapeutic targets."

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES:

With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/

Contact
NAPSRx
***@napsronline.org
1-800-284-1060
End
Source: » Follow
Email:***@napsronline.org Email Verified
Tags:Napsrx, CNPR Certification Program, Pharmaceutical Sales, Napsr, Training
Industry:Biotech, Health
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
NAPSRx PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share